Amplia Therapeutics Limited Stock price

Equities

ATX

AU0000023822

Biotechnology & Medical Research

Market Closed - Australian S.E. 12:57:22 2024-03-28 am EDT 5-day change 1st Jan Change
0.077 AUD 0.00% Intraday chart for Amplia Therapeutics Limited +2.67% -3.75%
Sales 2022 1.98M 1.29M Sales 2023 1.19M 775K Capitalization 16.49M 10.75M
Net income 2022 -3M -1.96M Net income 2023 -6M -3.91M EV / Sales 2022 7.87 x
Net cash position 2022 12.51M 8.15M Net cash position 2023 6.98M 4.55M EV / Sales 2023 7.99 x
P/E ratio 2022
-5.79 x
P/E ratio 2023
-2.64 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.92%
More Fundamentals * Assessed data
Dynamic Chart
1 week+2.67%
Current month+2.67%
1 month-3.75%
3 months-3.75%
6 months-2.53%
Current year-3.75%
More quotes
1 week
0.07
Extreme 0.074
0.08
1 month
0.07
Extreme 0.065
0.08
Current year
0.07
Extreme 0.065
0.08
1 year
0.06
Extreme 0.062
0.12
3 years
0.06
Extreme 0.062
0.35
5 years
0.05
Extreme 0.045
0.37
10 years
0.05
Extreme 0.045
18.30
More quotes
Managers TitleAgeSince
Founder - 00-05-30
Director of Finance/CFO - 23-09-24
Chief Operating Officer - 21-01-31
Members of the board TitleAgeSince
Corporate Secretary 62 13-10-10
Director/Board Member 68 15-09-01
Chairman - 18-05-03
More insiders
Date Price Change Volume
24-03-28 0.077 0.00% 201 547
24-03-27 0.077 +2.67% 126,117
24-03-26 0.075 -2.60% 49,177
24-03-25 0.077 0.00% 51,862
24-03-22 0.077 0.00% 39,358

Delayed Quote Australian S.E., March 28, 2024 at 12:57 am EDT

More quotes
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
More about the company
  1. Stock
  2. Equities
  3. Stock Amplia Therapeutics Limited - Australian S.E.